Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative … (NCT05205603) | Clinical Trial Compass
CompletedPhase 4
Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
China438 participantsStarted 2022-01-15
Plain-language summary
Endocopic remission rates of moderate to severe ulcerative colitis are low. Biologics including Vedolizumab, infliximab, and adalimumab are effective in induction and maintainence of ulcerative colitis. The role of 5-ASA in promoting a higher rate of endocsopic remission is unclear. We aim to evaluate the efficacy of combination of 5-ASA and biologics in treating ulcerative colitis.
Who can participate
Age range18 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients with moderate and severe ulcerative colitis;
✓. Subjects were above 18 years old and below 80 years;
✓. Indications of 5-ASA or biological treatment;
✓. According to the clinical symptoms, ulcerative colitis was diagnosed by endoscopic changes, pathological manifestations. The disease activity of UC was assessed according to the modified Mayo scoring system (modified Mayo: 6\~12 for patients with moderate to severe ulcerative colitis);
✓. If the subject is a woman, a pregnancy test at baseline is needed to exclude pregnancy. Female patients must follow the contraceptive recommendations of the project;
✓. Subjects must be able and willing to provide written informed consent and comply with the requirements of this study protocol.
Exclusion criteria
✕. No indications of 5-ASA or biological treatment;
✕. ulcerative colitis patients who had previously undergone a partial colectomy;
✕. Patients who are unable to use 5-ASA for a long time;
✕. Patients with severe, progressive, or uncontrolled kidney, liver, blood, or endocrine diseases or symptoms;
✕. Presence of infected persons, Patients with a contraindication to the use of biological agents such as C. difficile infection or other intestinal pathogens, active tuberculosis or intestinal tuberculosis infection, human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C (defined as: ① HBV: hepatitis B surface antigen (HBs Ag) positive (+), Or patients with positive for hepatitis B core antibody (HBcAb) and the qualitative test results of HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) meet the detection criteria; ② HCV: Any patient with an anti-HCV antibody (HCV Ab) -positive patient with a detectable HCV ribonucleic acid (RNA);
What they're measuring
1
endoscopic remission rate at 12 months
Timeframe: 12 months after first intervention administration
Trial details
NCT IDNCT05205603
SponsorSixth Affiliated Hospital, Sun Yat-sen University
✕. Patients with a history of gastrointestinal dysplasia, or dysplasia on any biopsy performed on endoscopy, excluding low-grade dysplasia lesions; known history of lymphoproliferative disease (including lymphoma), or signs and symptoms (e. g., lymphadenopathy and / or splenomegaly); patients with current or previous malignancy;